Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer
09 sept. 2024 03h00 HE
|
Anocca AB
SÖDERTÄLJE, Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces it will present its novel...
Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
30 mai 2024 06h00 HE
|
Anocca AB
SÖDERTÄLJE, Sweden and SAN FRANCISCO and KYOTO, Japan, May 30, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and...
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
14 mars 2024 02h00 HE
|
Anocca AB
NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc....
Anocca Appoints Martin Welschof to Board of Directors
13 févr. 2024 03h00 HE
|
Anocca AB
SÖDERTÄLJE, Sweden, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. ...
Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
04 janv. 2024 03h00 HE
|
Anocca AB
SÖDERTALJE, Sweden, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced it has received a certificate of good manufacturing practice (GMP)...
Anocca raises SEK 400 million for large-scale development of cancer cell therapies
31 mai 2023 01h30 HE
|
Anocca AB
SÖDERTÄLJE, Sweden, May 31, 2023 (GLOBE NEWSWIRE) -- Anocca AB today announces that the company has successfully raised SEK 400 million through an equity financing round led by AMF and...